kabutan

MediciNova,Inc.(4875) Summary

4875
TSE Standard
MediciNova,Inc.
227
JPY
-8
(-3.40%)
Mar 19, 3:30 pm JST
1.42
USD
Mar 19, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 19, 2026
Opening Mar 19, 9:00 am
228 JPY 1.42 USD
Previous Close Mar 18
235 JPY 1.48 USD
High Mar 19, 9:00 am
228 JPY 1.42 USD
Low Mar 19, 2:41 pm
224 JPY 1.40 USD
Volume
41,700
Trading Value
9.00M JPY 0.06M USD
VWAP
225.74 JPY 1.41 USD
Minimum Trading Value
22,700 JPY 142 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
111
Liquidity & Number of Trades
As of Mar 19, 2026
Liquidity
Mid
1-Year Average
194
1-Year High Nov 5, 2025
3,850
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 13, 2026 0 78,800
Mar 6, 2026 0 57,700
Feb 27, 2026 0 57,100
Feb 20, 2026 0 57,400
Feb 13, 2026 0 58,100
Company Profile
MediciNova, Inc. is a US-based pharmaceutical development venture focusing on treatments for conditions such as acute asthma attacks.
Sector
Pharmaceuticals
MediciNova, Inc. is a pharmaceutical development company headquartered in the United States, specializing in the development of novel therapeutics for serious diseases. Its lead development product, MN-166 (ibudilast), is being developed for indications including ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence, alcohol use disorder, and Long-COVID. MN-001 (tipelukast) is being developed for non-alcoholic fatty liver disease and idiopathic pulmonary fibrosis. Additionally, a treatment for phenylketonuria is included in the development pipeline. The company has received Fast Track and Orphan Drug designations from the US FDA for several of its development products, indicating a promising development pipeline.